Our results indicate that high circulating levels of transgenically expressed IL-22, chronic treatment with rmIL-22, or deficiency in endogenous IL-22 do not affect HFD-induced obesity and its metabolic consequences in mice. The gene discussed is IL22; the disease is obesity due to melanocortin 4 receptor deficiency.